Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Letters in Drug Design & Discovery
  4. Volume 21, Issue 13
  5. Article
Volume 21, Issue 13
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disease. Shugan Jiangzhi Decoction (SJD), a traditional Chinese medicine (TCM) formula which consists of six Chinese herbs, has been used for treating hyperlipidemia, obesity, and fatty liver in Guangdong Provincial Hospital of Traditional Chinese Medicine for over twenty years.

Objective

This study aims to elucidate the chemical basis and the molecular mechanism of SJD against NAFLD.

Methods

The main components of SJD were determined by High Performance Liquid Chromatography (HPLC). Then the high-fat diet (HFD)-induced NAFLD rat model was established. After treatment with different doses of SJD, the body weight of rats was measured weekly. On the last day of the experiments, the hepatic morphology, histopathology changes, and the serum lipid levels were detected. Then techniques of network pharmacology were employed to predict the anti-NAFLD mechanism of SJD. At last, the expression levels of proteins were measured by western blot to verify the mechanism.

Results

Nine chemical constituents of SJD were identified from HPLC fingerprint spectrum. For the experiment, NAFLD rat model was constructed successfully by feeding high-fat diet (HFD) for 8 weeks. The following treatment with SJD for 6 weeks decreased the fatty droplet accumulation in the liver obviously. Meanwhile, the serum level of high-density lipoprotein cholesterol (HDL-c) was increased, while the levels of low-density lipoprotein cholesterol (LDL-c), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were decreased after SJD treatment ( < 0.05). The results of network pharmacology indicated that SJD might improve NAFLD regulating the AMPK/PPAR signaling pathway. Then, the western blot assay confirmed that SJD activated the AMPK/PPAR signaling pathway in the liver of rats.

Conclusion

SJD improves HFD-induced NAFLD in rats AMPK/PPAR signaling pathway. Thus, our study suggests that SJD can serve as a therapeutic agent for the prevention and treatment of NAFLD.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180820666230828125057
2023-10-17
2025-06-30

  • From This Site

    /content/journals/lddd/10.2174/1570180820666230828125057
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BellentaniS. The epidemiology of non-alcoholic fatty liver disease.Liver Int.2017371818410.1111/liv.13299 28052624
     [Google Scholar]
  2. FriedmanS.L. Neuschwander-TetriB.A. RinellaM. SanyalA.J. Mechanisms of NAFLD development and therapeutic strategies.Nat. Med.201824790892210.1038/s41591‑018‑0104‑9 29967350
     [Google Scholar]
  3. CohenJ.C. HortonJ.D. HobbsH.H. Human fatty liver disease: Old questions and new insights.Science201133260371519152310.1126/science.1204265 21700865
     [Google Scholar]
  4. SeitzH.K. BatallerR. Cortez-PintoH. GaoB. GualA. LacknerC. MathurinP. MuellerS. SzaboG. TsukamotoH. Alcoholic liver disease.Nat. Rev. Dis. Primers2018411610.1038/s41572‑018‑0014‑7 30115921
     [Google Scholar]
  5. LewisJ.R. MohantyS.R. Nonalcoholic fatty liver disease: A review and update.Dig. Dis. Sci.201055356057810.1007/s10620‑009‑1081‑0 20101463
     [Google Scholar]
  6. SchmidtN.H. SvendsenP. Albarrán-JuárezJ. MoestrupS.K. BentzonJ.F. High-fructose feeding does not induce steatosis or non-alcoholic fatty liver disease in pigs.Sci. Rep.2021111280710.1038/s41598‑021‑82208‑1 33531575
     [Google Scholar]
  7. TilgH. MoschenA.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis.Hepatology20105251836184610.1002/hep.24001 21038418
     [Google Scholar]
  8. ZhengJ. LiZ. ManabeY. KimM. GotoT. KawadaT. SugawaraT. Siphonaxanthin, a carotenoid from green algae, inhibits lipogenesis in hepatocytes via the suppression of liver x receptor α activity.Lipids2018531415210.1002/lipd.12002 29446839
     [Google Scholar]
  9. HashmiS. WangY. ParharR.S. CollisonK.S. ConcaW. Al-MohannaF. GauglerR. A C. elegans model to study human metabolic regulation.Nutr. Metab.20131013110.1186/1743‑7075‑10‑31 23557393
     [Google Scholar]
  10. TorresD.M. WilliamsC.D. HarrisonS.A. Features, diagnosis, and treatment of nonalcoholic fatty liver disease.Clin. Gastroenterol. Hepatol.201210883785810.1016/j.cgh.2012.03.011 22446927
     [Google Scholar]
  11. FengQ. GouX. MengS. HuangC. ZhangY. TangY. WangW. XuL. PengJ. HuY. Qushi huayu decoction inhibits hepatic lipid accumulation by activating amp-activated protein kinase in vivo and in vitro.Evid. Based Complement. Alternat. Med.2013201311410.1155/2013/184358 23573117
     [Google Scholar]
  12. HardieD.G. AMP-activated protein kinase: Maintaining energy homeostasis at the cellular and whole-body levels.Annu. Rev. Nutr.2014341315510.1146/annurev‑nutr‑071812‑161148 24850385
     [Google Scholar]
  13. ChoK. KimS.J. ParkS.H. KimS. ParkT. Protective effect of Codonopsis lanceolata root extract against alcoholic fatty liver in the rat.J. Med. Food20091261293130110.1089/jmf.2009.0085 20041784
     [Google Scholar]
  14. HongM. LiS. WangN. TanH.Y. CheungF. FengY. A biomedical investigation of the hepatoprotective effect of radix salviae miltiorrhizae and network pharmacology-based prediction of the active compounds and molecular targets.Int. J. Mol. Sci.201718362010.3390/ijms18030620 28335383
     [Google Scholar]
  15. ZhangW. LiJ. WeiX. WangQ. YangJ. HouH. DuZ. WuX. Effects of dibutyl phthalate on lipid metabolism in liver and hepatocytes based on PPARα/SREBP-1c/FAS/GPAT/AMPK signal pathway.Food Chem. Toxicol.202114911202910.1016/j.fct.2021.112029 33508418
     [Google Scholar]
  16. FengY. WuZ. ZhouX. ZhouZ. FanW. Knowledge discovery in traditional chinese medicine: State of the art and perspectives.Artif. Intell. Med.200638321923610.1016/j.artmed.2006.07.005 16930966
     [Google Scholar]
  17. ZuoJ. WangX. LiuY. YeJ. LiuQ. LiY. LiS. Integrating network pharmacology and metabolomics study on anti-rheumatic mechanisms and antagonistic effects against methotrexate-induced toxicity of qing-luo-yin.Front. Pharmacol.20189147210.3389/fphar.2018.01472 30618762
     [Google Scholar]
  18. HopkinsA.L. Network pharmacology: The next paradigm in drug discovery.Nat. Chem. Biol.200841168269010.1038/nchembio.118 18936753
     [Google Scholar]
  19. FangJ. WangL. WuT. YangC. GaoL. CaiH. LiuJ. FangS. ChenY. TanW. WangQ. Network pharmacology-based study on the mechanism of action for herbal medicines in Alzheimer treatment.J. Ethnopharmacol.201719628129210.1016/j.jep.2016.11.034 27888133
     [Google Scholar]
  20. BiS.J. HuangY.X. FengL.M. YueS.J. ChenY.Y. FuR.J. XuD.Q. TangY.P. Network pharmacology-based study on immunomodulatory mechanism of danggui-yimucao herb pair for the treatment of RU486-induced abortion.J. Ethnopharmacol.202228211460910.1016/j.jep.2021.114609 34508802
     [Google Scholar]
  21. TuS.P. QuanteM. BhagatG. TakaishiS. CuiG. YangX.D. MuthuplaniS. ShibataW. FoxJ.G. PritchardD.M. WangT.C. IFN-γ inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T-cell apoptosis.Cancer Res.201171124247425910.1158/0008‑5472.CAN‑10‑4009 21512143
     [Google Scholar]
  22. GhiringhelliF. ApetohL. TesniereA. AymericL. MaY. OrtizC. VermaelenK. PanaretakisT. MignotG. UllrichE. PerfettiniJ.L. SchlemmerF. TasdemirE. UhlM. GéninP. CivasA. RyffelB. KanellopoulosJ. TschoppJ. AndréF. LidereauR. McLaughlinN.M. HaynesN.M. SmythM.J. KroemerG. ZitvogelL. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors.Nat. Med.200915101170117810.1038/nm.2028 19767732
     [Google Scholar]
  23. DinizT.A. de LimaJuniorE.A. TeixeiraA.A. BiondoL.A. da RochaL.A.F. ValadãoI.C. SilveiraL.S. Cabral-SantosC. de SouzaC.O. Rosa NetoJ.C. Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-α signaling in obese mice.Life Sci.202126611886810.1016/j.lfs.2020.118868 33310034
     [Google Scholar]
  24. BugianesiE. LeoneN. VanniE. MarchesiniG. BrunelloF. CarucciP. MussoA. De PaolisP. CapussottiL. SalizzoniM. RizzettoM. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma.Gastroenterology2002123113414010.1053/gast.2002.34168 12105842
     [Google Scholar]
  25. MarchesiniG. BriziM. BianchiG. TomassettiS. BugianesiE. LenziM. McCulloughA.J. NataleS. ForlaniG. MelchiondaN. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome.Diabetes20015081844185010.2337/diabetes.50.8.1844 11473047
     [Google Scholar]
  26. GrundyS.M. BrewerH.B.Jr CleemanJ.I. SmithS.C.Jr LenfantC. Definition of metabolic syndrome: Report of the national heart, lung, and blood institute/american heart association conference on scientific issues related to definition.Circulation2004109343343810.1161/01.CIR.0000111245.75752.C6 14744958
     [Google Scholar]
  27. ReisinE. AlpertM.A. Definition of the metabolic syndrome: Current proposals and controversies.Am. J. Med. Sci.2005330626927210.1097/00000441‑200512000‑00003 16355010
     [Google Scholar]
  28. ZhangM. YuanY. WangQ. LiX. MenJ. LinM. The chinese medicine chai hu li zhong tang protects against non-alcoholic fatty liver disease by activating AMPKα.Biosci. Rep.2018386BSR2018064410.1042/BSR20180644 30291215
     [Google Scholar]
  29. LiangZ. ChenX. ShiJ. HuH. XueY. UngC.O.L. Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: A systematic literature review of randomized controlled trials.Chin. Med.2021161910.1186/s13020‑020‑00422‑x 33430929
     [Google Scholar]
  30. VazirianM. NabaviS.M. JafariS. ManayiA. Natural activators of adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) and their pharmacological activities.Food Chem. Toxicol.2018122697910.1016/j.fct.2018.09.079 30290216
     [Google Scholar]
  31. DusabimanaT. ParkE.J. JeJ. JeongK. YunS.P. KimH.J. KimH. ParkS.W. P2Y2R deficiency ameliorates hepatic steatosis by reducing lipogenesis and enhancing fatty acid β-oxidation through ampk and pgc-1α induction in high-fat diet-fed mice.Int. J. Mol. Sci.20212211552810.3390/ijms22115528 34073834
     [Google Scholar]
/content/journals/lddd/10.2174/1570180820666230828125057
Loading
Shugan Jiangzhi Decoction Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) via Regulating AMPK/PPAR Signaling Pathway
Letters in Drug Design & Discovery 21, 2740 (2024); https://doi.org/10.2174/1570180820666230828125057
/content/journals/lddd/10.2174/1570180820666230828125057
/content/journals/lddd/10.2174/1570180820666230828125057
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): AMPK/PPAR signaling pathway; Chinese medicine; high performance liquid chromatography (HPLC); network pharmacology; nonalcoholic fatty liver disease (NAFLD); Shugan jiangzhi decoction (SJD)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test